Molecular mode of action of NKP-1339-a clinically investigated ruthenium-based drug - involves Nrf2 translocation and ER-associated protein degradation in colon carcinoma cell lines

L. S. Flocke; R. Trondl; L. Bamonti; M. A. Jakupec; B. K. Keppler

Molecular mode of action of NKP-1339-a clinically investigated ruthenium-based drug - involves Nrf2 translocation and ER-associated protein degradation in colon carcinoma cell lines

L. S. Flocke, R. Trondl, L. Bamonti, M. A. Jakupec, B. K. Keppler

Department of Inorganic Chemistry

Publications: Contribution to journal › Meeting abstract/Conference paper › Peer Reviewed

Original language	English
Pages (from-to)	S59-S59
Number of pages	1
Journal	European Journal of Cancer
Volume	51
Publication status	Published - Sept 2015
Event	European Cancer Congress - Wien, Austria Duration: 25 Sept 2015 → 29 Sept 2015 http://www.esmo.org/Conferences/European-Cancer-Congress-2015

Austrian Fields of Science 2012

104003 Inorganic chemistry
301904 Cancer research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{37a4396824f84bf69b5a3d4ff8c7ea68,

title = "Molecular mode of action of NKP-1339-a clinically investigated ruthenium-based drug - involves Nrf2 translocation and ER-associated protein degradation in colon carcinoma cell lines",

author = "Flocke, {L. S.} and R. Trondl and L. Bamonti and Jakupec, {M. A.} and Keppler, {B. K.}",

note = " Accession Number: WOS:000361887400184 ; European Cancer Congress ; Conference date: 25-09-2015 Through 29-09-2015",

year = "2015",

month = sep,

language = "English",

volume = "51",

pages = "S59--S59",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

url = "http://www.esmo.org/Conferences/European-Cancer-Congress-2015",

}

Molecular mode of action of NKP-1339-a clinically investigated ruthenium-based drug - involves Nrf2 translocation and ER-associated protein degradation in colon carcinoma cell lines. / Flocke, L. S.; Trondl, R.; Bamonti, L. et al.
In: European Journal of Cancer, Vol. 51, 09.2015, p. S59-S59.

Publications: Contribution to journal › Meeting abstract/Conference paper › Peer Reviewed

TY - JOUR

T1 - Molecular mode of action of NKP-1339-a clinically investigated ruthenium-based drug - involves Nrf2 translocation and ER-associated protein degradation in colon carcinoma cell lines

AU - Flocke, L. S.

AU - Trondl, R.

AU - Bamonti, L.

AU - Jakupec, M. A.

AU - Keppler, B. K.

N1 - Accession Number: WOS:000361887400184

PY - 2015/9

Y1 - 2015/9

M3 - Meeting abstract/Conference paper

SN - 0959-8049

VL - 51

SP - S59-S59

JO - European Journal of Cancer

JF - European Journal of Cancer

T2 - European Cancer Congress

Y2 - 25 September 2015 through 29 September 2015

ER -